ARPA-H Archives - EverGlade Consulting

ARPA-H

curative cell therapies_DECIDE-ET_ARPA-H

Decentralized Engineering of Cells Informed by Dynamic Evidence Exploration Topic

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

ARPA-H_DECIDE-ET_Solicitation_DRAFT Overview of Exploration Topic Although Academic Medical Centers (AMCs) have developed many advanced therapies for rare and fatal diseases,  access to AMCs remains limited due to outdated production methods and inadequate quality validation. To enhancing quality assurance technologies at AMCs, the Advanced Research Projects Agency for Health (ARPA-H) has initiated the Decentralized Engineering of […]

Decentralized Engineering of Cells Informed by Dynamic Evidence Exploration Topic Read More »

in silico modeling for ADME-Tox simulation

Computational ADME-Tox Analysis for Safer Therapeutics (CATALYST) Innovative Solutions Opening

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

CATALYST_ISO_(DRAFT) Overview of CATALYST Solicitation Current in vivo animal model testing methods often fail to predict human drug safety accurately, leading to inefficiencies and high costs. The Health Science Futures (HSF) Office of the Advanced Research projects Agency for Health (ARPA-H) has introduced the CATALYST program to transform drug development. This program will foster the

Computational ADME-Tox Analysis for Safer Therapeutics (CATALYST) Innovative Solutions Opening Read More »

Gene therapy

EverGlade Consulting Helps Cirsium Secure up to $61 Million in ARPA-H Funding

Leave a Comment / ARPA-H, EverGlade Insights / By

EverGlade Consulting, a national consulting firm, has helped Cirsium Biosciences successfully secure up to $61 million in funding to create a rapid, safe, scalable, and low-cost plant-based manufacturing platform to drastically reduce production time and cost of viral vector-based gene therapies. How Funding Will Be Used The $61 million in ARPA-H funding will enable Cirsium

EverGlade Consulting Helps Cirsium Secure up to $61 Million in ARPA-H Funding Read More »

cancer moonshot

Cancer Moonshot and the ARPA-H Cancer Funding Landscape

Leave a Comment / ARPA-H, EverGlade Insights / By

Even with incredible scientific progress, cancer remains the second highest leading cause of death in the United States (U.S.) and one of the highest causes of death worldwide. To accelerate and bolster the great innovations made in therapeutics, diagnostics, and patient care, the Biden-Harris administration has reignited the Cancer Moonshot initiative. This program, introduced by

Cancer Moonshot and the ARPA-H Cancer Funding Landscape Read More »

cell therapies

ARPA-H Issues Draft Solicitation for Autologous Cell Therapy (ACT)

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

DECIDE_ET_Solicitation_DRAFT The Advanced Research Projects Agency for Health (ARPA-H) has introduced the Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic (ET), representing a crucial initiative designed to revolutionize the production and validation of autologous cell therapies. This ET targets significant enhancements in the production processes at Academic Medical Centers (AMCs), focusing on

ARPA-H Issues Draft Solicitation for Autologous Cell Therapy (ACT) Read More »

cancer screening technologies

ARPA-H Announces RFP for Cancer Intervention and Detection

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

24-SOL-109+POSEIDON+DRAFT+ISO_9+AUG+24 The Advanced Research Projects Agency for Health (ARPA-H) has issued a Request for Proposals (RFP) for the POSEIDON program, a groundbreaking initiative aimed at advancing cancer screening technologies. The Platform Optimizing SynBio for Early Intervention and Detection in Oncology (POSEIDON) seeks to develop innovative, non-invasive tests that can detect multiple cancers at an early

ARPA-H Announces RFP for Cancer Intervention and Detection Read More »

Senior chemist analysing blood sample while working overtime in chemistry equipped laboratory.

ARPA-H Announces Proposers’ Day for New POSEIDON Program

Leave a Comment / ARPA-H, EverGlade Insights / By

Proposers’ Day Notice 24-SOL-109+POSEIDON+DRAFT+ISO_9+AUG+24 The Advanced Research Projects Agency for Health (ARPA-H) has recently unveiled an exciting initiative named POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in ONcology). This program aims to drastically shift the current landscape of cancer detection through innovative, synthetic biology-based approaches. As part of this groundbreaking venture, ARPA-H is

ARPA-H Announces Proposers’ Day for New POSEIDON Program Read More »

African American woman in a technically advanced career

ARPA-H Announces Small Business Opportunities

Leave a Comment / ARPA-H, EverGlade Insights / By

The Advanced Research Projects Agency for Health (ARPA-H) has announced an upcoming solicitation for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) contracts for FY2024. The initiative targets innovative firms capable of conducting cutting-edge research and development, with a focus on commercializing the results. The solicitation includes opportunities for Phase I, Direct to Phase II, and Fast Track contracts.

ARPA-H Announces Small Business Opportunities Read More »

Scroll to Top